Aurora Achieves Significant Progress in Disease Resistance Research

Core Insights - Aurora Cannabis Inc. has made significant advancements in research related to powdery mildew resistance, reinforcing its leadership in cannabis science [1][2] - The company is transitioning from research to production trials for cultivars with verified PM2 resistance, aiming for commercialization later this year [3][4] Research and Development - Aurora has conducted multiple rounds of genetic crosses to integrate PM2 resistance into elite breeding lines, ensuring that high-performing genetics maintain quality traits essential for patients and consumers [2] - The proprietary genetic marker technology for PM2 was developed at Aurora's research facility, building on previous collaborations with the University of British Columbia and Genome British Columbia [4] Production and Commercialization - The company is validating its research through production trials at the Aurora Ridge manufacturing facility, which is a critical step toward the commercialization of powdery mildew-resistant cultivars [3] - Successful production trials are expected to protect plant health, reduce operational costs, and improve product quality, with plans to commercialize these cultivars later this year [4] Industry Position and Innovation - Aurora is committed to pushing the boundaries of cannabis science by integrating advanced breeding techniques with rigorous research, setting new standards for quality and efficiency [5] - The company holds patent-pending intellectual property in multiple regions, including Canada, the United States, Europe, Australia, New Zealand, and Israel [5]